Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jack Jumper Ant venom + delta-inulin
- Development stage
- Unknown
- Lead developer
- Tasmanian Jack Jumper Allergy Research Group
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This investigational immunotherapy product combines Jack Jumper Ant (Myrmecia pilosula) venom with the delta-inulin adjuvant (brand name Advax) for the treatment of Jack Jumper Ant allergy. Developed by the Central Adelaide Local Health Network in collaboration with researchers at the Royal Adelaide and Royal Hobart Hospitals, the product aims to facilitate immune tolerance. Delta-inulin, a polysaccharide-based biologic adjuvant supplied by Vaxine Pty Ltd, exists as semicrystalline microparticles that enhance the immune response. By incorporating this adjuvant, the therapy seeks to achieve protective immune responses (increased IgG4 and decreased IgE) using lower maintenance doses of venom (25 or 50 mcg), thereby reducing the risk of adverse systemic reactions and lowering treatment costs. It is currently being evaluated in the Phase 1/2 'JumpVax' clinical trial.
- Brand names
- AdvaxJumpVax
- Other names
- JJA VIT + delta-inulinJack Jumper Ant venom immunotherapy with AdvaxJack Jumper Ant venom immunotherapy with delta-inulin adjuvant
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on Jack Jumper Ant venom + delta-inulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jack Jumper Ant venom + delta-inulin.